Critics say the changes would damage India's position as a leading provider of generic drugs - essentially "copycat" versions of those which fall out of patent
India's overall score has increased substantially from 25% (8.75 out of 35) in the 5th edition of the Index to 30% (12.03 out of 40) in the 6th edition
